Of note, Magrangeas et al. [41] found that low pre-treatment levels of NF-kB were associated with a higher response rate to bortezomib-based induction in newly diagnosed MM, but we were unable to find a similar correlation between pre-treatment NF-kB activity and bortezomib. This evidence concerns the gene NFKB1 and Miyoshi myopathy.